吲哚青绿
乳腺癌
纳米探针
体内
放射治疗
医学
癌症
磁共振成像
癌症研究
贝伐单抗
外科肿瘤学
荧光寿命成像显微镜
荧光
病理
内科学
放射科
材料科学
纳米技术
化疗
生物
纳米颗粒
生物技术
物理
量子力学
作者
Yong‐Qu Zhang,Wanling Liu,Xiangjie Luo,Junpeng Shi,Yunkao Zeng,Weiling Chen,Wen‐He Huang,Yuanyuan Zhu,Wen Gao,Ronghui Li,Zi-He Ming,Lixin Zhang,Rui‐Qin Yang,Jiazheng Wang,Guo‐Jun Zhang
标识
DOI:10.1002/advs.202205294
摘要
Breast-conserving surgery (BCS) is the predominant treatment approach for initial breast cancer. However, due to a lack of effective methods evaluating BCS margins, local recurrence caused by positive margins remains an issue. Accordingly, radiation therapy (RT) is a common modality in patients with advanced breast cancer. However, while RT also protects normal tissue and enhances tumor bed doses to improve therapeutic effects, current radiosensitizers cannot meet these urgent clinical needs. To address this, a novel self-assembled multifunctional nanoprobe (NP) gadolinium (Gd)-diethylenetriaminepentaacetic acid-human serum albumin (HSA)@indocyanine green-Bevacizumab (NPs-Bev) is synthesized to improve the efficacy of fluorescence-image-guided BCS and RT. Fluorescence image guidance of the second near infrared NP improves complete resection in tumor-bearing mice and accurately discriminates between benign and malignant mammary tissue in transgenic mice. Moreover, targeting tumors with NPs induces more reactive oxygen species under X-ray radiation therapy, which not only increases RT sensitivity, but also reduces tumor progression in mice. Interestingly, self-assembled NPs-Bev using HSA, the magnetic resonance contrast agent and Bevacizumab-targeting vascular growth factor A, which are clinically safe reagents, are safe in vitro and in vivo. Therefore, the novel self-assembled NPs provide a solid precision therapy platform to treat breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI